Master10 Proprietary Question Bank - Automated scraping, spidering, or harvesting is strictly prohibited.
Science & Technology25 Essential Exam Concepts
Gene Therapy: Viral Vectors, CRISPR-Cas9, In Vivo & Ex Vivo Biotechnology
In biotechnology, molecular medicine, and clinical therapeutics, Gene Therapy represents a groundbreaking frontier of modern healthcare aimed at treating, preventing, or curing congenital genetic disorders and acquired diseases by directly altering, repairing, or replacing abnormal genetic instructions within a patient's cells. Rather than relying upon traditional pharmaceutical drugs that merely alleviate symptoms by modifying downstream proteins, gene therapy targets the root biological etiology of disease at the genomic level. By introducing functional therapeutic genes, silencing mutated overexpressed sequences, or precisely rewriting aberrant DNA base pairs, gene therapy transforms previously fatal hereditary conditions into manageable or curable disorders.
The technological execution of gene therapy operates through two primary clinical paradigms: Ex Vivo and In Vivo delivery. In Ex Vivo Gene Therapy, target cells (such as hematopoietic bone marrow stem cells or patient T-lymphocytes) are harvested directly from the patient, genetically modified in a sterile laboratory setting using therapeutic vectors, expanded in culture, and re-infused into the patient's bloodstream. This approach forms the foundation of Chimeric Antigen Receptor (CAR) T-cell therapies (such as the indigenous Indian CAR-T therapy NexCAR19 approved in 2023 for refractory lymphomas). Conversely, In Vivo Gene Therapy involves injecting therapeutic genetic material directly into the patient's body (such as into the retina or spinal canal) encapsulated within modified Viral Vectors—primarily non-pathogenic Adeno-Associated Viruses (AAV) or Lentiviruses that function as microscopic biological delivery shuttles.
The discipline experienced a revolutionary leap with the development of programmable Gene Editing technologies, most notably the CRISPR-Cas9 system pioneered by Nobel laureates Emmanuelle Charpentier and Jennifer Doudna in 2012. Derived from an ancient bacterial adaptive immune system, CRISPR uses a synthetic guide RNA (gRNA) to direct the Cas9 endonuclease enzyme to an exact genomic address, where it creates a precise double-strand break, allowing the cell's natural repair machinery to knock out defective genes or splice in healthy sequences. In medical ethics and international law, a fundamental distinction is maintained between Somatic Cell Gene Therapy (where genetic alterations are confined to the patient's body tissues and are non-heritable) and Germline Gene Therapy (which modifies reproductive gametes or embryos, creating permanent heritable changes that are strictly restricted or prohibited worldwide).